Compare Bristol-Myers Squibb Co (BMY) vs Blackstone Inc (BX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Blackstone Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B), while Blackstone Inc trades at $145.31 (market cap $117.44B). The key difference: Bristol-Myers Squibb Co and Blackstone Inc are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | BX | |
|---|---|---|
Market Cap | $129.94B | $117.44B |
Sector | Health | Financials |
52-Week High | $65.89 | $188.68 |
52-Week Low | $42.60 | $102.12 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Blackstone (BX) trades at $141.67, up 3.31% today, near its consensus price target of $144.00. The stock shows strong bullish technical signals and has consistently beaten earnings estimates in recent quarters. Recent news highlights strategic acquisitions, including a stake in Air Canada's Aeroplan program and a $25.3 billion Australian home loan portfolio purchase from HSBC, signaling aggressive growth and diversification.
Outlook remains positive with robust revenue growth and high profitability, though elevated valuation ratios and overbought RSI levels suggest near-term caution. Key risks include market volatility and integration challenges from recent deals. Analyst consensus is strongly bullish, supporting a favorable long-term view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
